Elbasvir- CAS 1370468-36-2

Elbasvir (MK-8742, cas 1370468-36-2) is a small-molecule inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection.

Elbasvir possesses activity against genotype 1a, 1b, and 3 in vitro, including against some viral variants resistant to other NS5A inhibitors. In a phase 1b dose escalation study, Elbasvir once daily for 5 days resulted in mean reductions in HCV RNA levels of 3.7 to 5.1 log10IU/ml in patients with genotype 1a or 1b infections given 5 to 50 mg/day and of 3 log10 IU/ml in patients with genotype 3 given 50 or 100 mg/day. In later phase 2 trials, treatment with Elbasvir combined with Grazoprevir (MK-5172, an investigational once-daily NS3/4A protease inhibitor) with or without Ribavirin for 12 weeks produced rates of sustained virological response at week 12 (SVR12) of 87 to 98% for patients with genotype 1 infections, including in historically difficult-to-treat subgroups.

Catalog Number: I001427

CAS Number: 1370468-36-2

PubChem Substance ID:347747243

Molecular Formula: C49H55N9O7

Molecular Weight:882.02

Purity: ≥95%

* For research use only. Not for human or veterinary use.


Molecular Formula: C49H55N9O7
Molecular Weight882.02
Solubility10 mM in DMSO
Storage3 years -20C powder

Computed Descriptor